Safety of Tinted Soft Scleral Eye Shields When IPL is Applied on Eyelids

Completed · Not applicable

Conditions studied: Dry Eye Disease, Meibomian Gland Dysfunction

In brief

The purpose of this study is to verify the safety of tinted soft scleral eye shields when IPL is applied directly on eyelids.

Key facts

Study ID

NCT05168670

Run by

Lumenis Be Ltd.

People needed

20

Starts

2021-12-21

Expected to finish

2022-01-25

Last updated by the study team

2022-05-26

Who can join

Age: 22 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is able to read, understand and sign an IC form
• 22 or older
• Self-assessed symptoms are consistent with dry eye (SPEED score ≥ 10)
• Signs of MGD, as detected in biomicroscopy
• Fitzpatrick skin type I-V
• Subject is willing to comply with all study procedures, including return to the clinic 1 day and 1 week after the first and only treatment within the scope of the study

You may not qualify if…

• • Fitzpatrick skin type VI
• Ocular surgery or eyelid surgery, within 3 months prior to screening
• Recent ocular trauma, within 3 months prior to screening
• Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area
• Severe active allergies, or other severe uncontrolled eye disorders affecting the ocular surface
• Uncontrolled infections or uncontrolled immunosuppressive diseases
• Subjects with ocular infections requiring the use of antibiotic treatment, within 3 months prior to screening
• Legally blind in either eye
• Ocular surface abnormality that may compromise corneal integrity in either eye (e.g., keratoconus, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, prior chemical burn)
• Eyelid abnormalities that affect lid function in either eye, including: entropion, ectropion, tumor, blepharospasm, lagophthalmos, severe trichiasis, and severe ptosis
• Prior history of cold sores or rashes in the perioral area or in the planned treatment area that could be stimulated by light at a wavelength of 560 nm to 1200 nm, including: Herpes simplex 1 \& 2, Systemic Lupus erythematosus, and porphyria
• Within 3 months prior to screening, use of photosensitive medication and/or herbs that may cause sensitivity to 560-1200 nm light exposure, including: Isotretinoin, Tetracycline, Doxycycline, and St. John's Wort
• Over exposure to sun, within 4 weeks prior to screening
• Moderate to severely compromised corneal health as assessed by corneal fluorescein staining
• Trans-illumination defects
• Anisocoria or pupil deformation
• Anterior chamber inflammation
• Media opacities (cataract, posterior capsule opacification, corneal edema, etc.) that preclude clear visualization of the anterior segment and retina
• Any condition revealed whereby the investigator deems the subject inappropriate for this study

Where it is running

• Toyos Clinic — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.